← Back to Search

Cancer Screening for Ovarian Cancer

N/A

Waitlist Available

Led By Christine D Berg

Research Sponsored by National Cancer Institute (NCI)

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up events through 13 years of follow-up or through december 31, 2009; median follow-up 11.9 years.

Awards & highlights

Study Summary

This trial is testing whether screening for different types of cancer can reduce deaths from those cancers.

Who is the study for?

This trial is for older individuals who may be at risk of ovarian cancer, including germ cell tumors. Participants should be willing to undergo screening tests like biomarker analysis and ultrasound imaging, as well as fill out health questionnaires.Check my eligibility

What is being tested?

The study is testing the effectiveness of various screening methods in diagnosing cancers early, specifically focusing on ovarian cancer. It's part of a larger effort that includes prostate, lung, colon, and rectal cancers.See study design

What are the potential side effects?

Since this trial involves non-invasive screening methods such as laboratory tests and ultrasound imaging rather than drug treatments, side effects are minimal but could include discomfort or anxiety during procedures.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ events through 13 years of follow-up or through december 31, 2009; median follow-up 11.9 years.

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~events through 13 years of follow-up or through december 31, 2009; median follow-up 11.9 years.

This trial's timeline: 3 weeks for screening, Varies for treatment, and events through 13 years of follow-up or through december 31, 2009; median follow-up 11.9 years. for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Ovarian Cancer Death Rates (Including Primary Peritoneal and Fallopian Tube Cancers)

Ovarian Cancer Deaths (Including Primary Peritoneal and Fallopian Tube Cancers)

Secondary outcome measures

Complications of Diagnostic Evaluation (DE) Following a Positive Screening Test

Death Rates From All Causes

Deaths From All Causes

+12 more

Trial Design

2Treatment groups

Active Control

Group I: Ovarian ScreeningActive Control3 Interventions

Participants undergo blood sample collection for CA125 analysis at baseline annually for 5 years. Serum that is not used in the study will be stored in an NCI biorepository. Participants also undergo an OVR (discontinued in December 1998) and TVU at baseline and annually for 3 years. Participants complete a DQX at baseline and DHQ at year 3. An ADU (previously referred to as the PSH questionnaire) is mailed to each participant annually for 13 years to identify all prevalent and incident cancers of the ovaries as all deaths that occur among both screened and control subjects during the trial.

Group II: ControlActive Control1 Intervention

Participants receive standard medical care. Participants complete a DHQ at baseline.

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

National Cancer Institute (NCI)Lead Sponsor

13,657 Previous Clinical Trials

40,855,451 Total Patients Enrolled

286 Trials studying Ovarian Cancer

73,766 Patients Enrolled for Ovarian Cancer

Christine D BergPrincipal InvestigatorNational Cancer Institute (NCI)

3 Previous Clinical Trials

386,486 Total Patients Enrolled

Media Library

Ultrasonography Clinical Trial Eligibility Overview. Trial Name: NCT01696994 — N/A

Ovarian Cancer Research Study Groups: Ovarian Screening, Control

Ovarian Cancer Clinical Trial 2023: Ultrasonography Highlights & Side Effects. Trial Name: NCT01696994 — N/A

Ultrasonography 2023 Treatment Timeline for Medical Study. Trial Name: NCT01696994 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any open enrolment opportunities for participants in this research?

"Accessing the information listed on clinicaltrials.gov, it is evident that this study is not recruiting participants at this current juncture. Although initially posted in November 1993 and last updated in August 2022, there are a total of 104 other trials which require patients right now."

Answered by AI

To what end is this research endeavor striving?

"This medical trial is evaluating Ovarian cancer Deaths (Including Primary Peritoneal and Fallopian Tube Cancers) as its primary outcome, spanning an 11.9 year follow-up period or through December 31st 2009. Secondary outcomes include the rate of Ovarian Cancer Incidence Rates (confirmed by record abstraction), Death Rates From All Causes, and T3 CA-125 Screening Results."

Answered by AI

Does the criterion for this research include individuals above four decades of age?

"The requirements for joining this medical trial are a minimum age of 55 and a maximum of 74. Additionally, there are 41 trials specialized towards those under 18 years old and 68 studies meant to serve the senior population."

Answered by AI

Who has the necessary credentials to be eligible for inclusion in this investigation?

"To enroll in this study, patients with ovarian germ cell tumours must be between 55 and 74 years of age. In total, the medical trial requires 78216 participants to complete its clinical requirements."

Answered by AI

Recent research and studies

Clinical NutritionJournal

Vitamin K Intake and Breast Cancer Incidence and Death: Results from a Prospective Cohort Study

Wang, Kang, Qianxue Wu, Zhuyue Li, Michael K. Reger, Yongfu Xiong, Guochao Zhong, Qing Li, et al.. 2021. “Vitamin K Intake and Breast Cancer Incidence and Death: Results from a Prospective Cohort Study”. Clinical Nutrition. Elsevier BV. doi:10.1016/j.clnu.2020.11.009.

Clinical Breast CancerJournal

Breast Cancer Incidence and Mortality in Relation to Hormone Replacement Therapy Use Among Postmenopausal Women: Results from a Prospective Cohort Study

Jiang, Yi, QinLi Xie, and Rong Chen. 2022. “Breast Cancer Incidence and Mortality in Relation to Hormone Replacement Therapy Use Among Postmenopausal Women: Results from a Prospective Cohort Study”. Clinical Breast Cancer. Elsevier BV. doi:10.1016/j.clbc.2021.06.010.

clinicaltrials.govStudy

Screening for Ovarian Cancer in Older Patients (PLCO Screening Trial)

1993. "Screening for Ovarian Cancer in Older Patients (PLCO Screening Trial)". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT01696994.